CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-19). The draft was written by AI, the existence of all 5 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 617 · Search date 2026-07-19 · Methodology v0.6

Modafinil,
does it really help with Improved mental energy, alertness, and focus in healthy people?

30-Second Summary
C
Evidence Grade C · 43 · Safety warning
Modafinil can maintain wakefulness during sleep pressure, but evidence for reliable mental-energy and focus enhancement in healthy people is limited
What the
research shows
Modafinil is rated C for cognitive and focus enhancement in healthy people who have slept normally. A meta-analysis of 19 placebo-controlled studies found a small but significant overall cognitive effect, g=0.10 (95% CI 0.05 to 0.15), and a separate meta-analysis reported SMD 0.12. These are positive surrogate signals, but the effects are very small and come mainly from single-dose laboratory tasks, so they do not support B or guarantee everyday productivity or durable benefit. Wakefulness during sleep deprivation or night work is a separate claim, and evidence does not establish treatment of ordinary fatigue or replacement of sleep. Dependence, insomnia, cardiovascular concerns, and off-label use remain separate safety warnings.
What the
ads claim
Online promotion turns a wake-promoting effect into limitless focus, mental fuel, erased fatigue, and equivalent performance on less sleep. Temporarily suppressing sleepiness under deprivation is not the same as improving higher cognition, creativity, or long-term productivity in healthy people.
*

Useful facts when choosing a product

  • Modafinil is a prescription drug used to improve wakefulness in narcolepsy, excessive sleepiness associated with obstructive sleep apnea, and shift-work sleep disorder; healthy-person focus enhancement is not an approved indication.
  • Provigil is a Schedule IV controlled substance in the United States and has misuse and dependence potential, so it should not be shared or obtained from unregulated nonprescription sources.
  • Headache, anxiety, insomnia, and nausea can occur, while blood-pressure or heart-rate changes, psychiatric symptoms, and rare serious skin reactions require caution and prompt evaluation of any rash.
  • Modafinil can reduce the effectiveness of steroidal contraceptives, and additional contraception is required during treatment and for the label-specified period after discontinuation.
Gap Measurement · Verdict 617 · C 43
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The 2019 meta-analysis by Kredlow and colleagues pooled placebo-controlled single-dose studies in healthy non-sleep-deprived adults and reported an overall cognitive effect of g=0.10 (95% CI 0.05 to 0.15). The 2020 meta-analysis by Roberts and colleagues likewise found a small significant overall effect, SMD 0.12 (P=.01). Battleday and Brem identified executive-function signals alongside mixed domain results and possible impairment of creativity. The 32-person night-work trial by Walsh and colleagues belongs to the separate high-sleep-pressure wakefulness axis and is not combined with normal daytime cognition. Approved sleep-disorder indications do not constitute recognition of a healthy nootropic claim.

02

Why this is classified as C (43)

C. Overall cognitive effects of g=0.10 (95% CI 0.05 to 0.15) and SMD 0.12 across two meta-analyses are very small but statistically significant positive signals. Because the evidence is dominated by single-dose laboratory tasks and surrogate outcomes without direct everyday productivity or long-term benefit, the grade is C with 43 points rather than B. Sleep-deprivation and night-work wakefulness are separate, while dependence, insomnia, cardiovascular, psychiatric, and dermatologic risks remain separate safety warnings.

Counterpoint. When narcolepsy or shift-work sleep disorder is suspected, modafinil may be used after sleep-specialist evaluation for an indicated condition. For ordinary fatigue and insufficient sleep, assessing sleep duration and quality, work schedule, depression or anxiety, anemia, thyroid disease, and other causes takes priority over off-label self-use.

Rejudgment record. Reassessment (cross-check reflected) — Raised D to C because meta-analyses in healthy non-sleep-deprived adults found small but significant overall cognitive effects, g=0.10 (95% CI 0.05 to 0.15) and SMD 0.12, while withholding B because the effects were very small and based mainly on single-dose laboratory tasks and surrogates; separated sleep-deprivation and night-work wakefulness from ordinary fatigue and sleep replacement

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Cognitive and focus enhancement in healthy peopleCMeta-analytic g=0.10 was small but significant; evidence is based on single-dose laboratory tasks and surrogate outcomes.
Maintenance of wakefulness during sleep deprivation or shift work?A separate axis and not part of this verdict.
Treatment of fatigue or replacement of sleep?Insufficient authorization and efficacy evidence.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Battleday RM, Brem AK. 2015Systematic review in healthy non-sleep-deprived adults24Academic research; no manufacturer sponsorship identified in accessible article informationAttention, executive function, learning and memory, decision-making, and creativity tasksSome executive-function outcomes improved, but only about half of attention, learning, and memory findings were positive and some creativity outcomes worsened.Key non-sleep-deprived synthesis with mixed findings
Kredlow MA et al. 2019Systematic review and meta-analysis67Boston University and academic researchAttention, executive function, learning and memory, and other cognitive domainsThe overall cognitive effect was small but significant, g=0.10 (95% CI 0.05 to 0.15).Key quantitative synthesis with a very small significant surrogate effect
Walsh JK et al. 2004Randomized double-blind placebo-controlled simulated-night-shift trial32Supported by CephalonMaintenance of Wakefulness Test, psychomotor vigilance, subjective alertness, and executive functionDuring four simulated night shifts, 200 mg improved alertness, vigilance, and selected executive-function outcomes.Separate positive evidence under sleep pressure, indirect for normal daily life
§

Receipt — 5 References

All 5 cited sources were verified for existence at the original page (as of 2026-07-19).

Battleday RM, Brem AK. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review. Eur Neuropsychopharmacol. 2015;25(11):1865-1881. PMID: 26381811. DOI: 10.1016/j.euroneuro.2015.07.028.
checked
Kredlow MA, Keshishian A, Oppenheimer S, Otto MW. The Efficacy of Modafinil as a Cognitive Enhancer: A Systematic Review and Meta-Analysis. J Clin Psychopharmacol. 2019;39(5):455-461. PMID: 31433334. DOI: 10.1097/JCP.0000000000001085.
checked
Roberts CA, Jones A, Sumnall H, Gage SH, Montgomery C. How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine. Eur Neuropsychopharmacol. 2020;38:40-62. PMID: 32709551. DOI: 10.1016/j.euroneuro.2020.07.002.
checked
Walsh JK, Randazzo AC, Stone KL, Schweitzer PK. Modafinil improves alertness, vigilance, and executive function during simulated night shifts. Sleep. 2004;27(3):434-439. PMID: 15164895. DOI: 10.1093/sleep/27.3.434.
checked
DailyMed. PROVIGIL (modafinil) tablets, for oral use, C-IV. Revised 2025. PMID: none. DOI: none.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none

Cite this verdict

Modafinil x improved mental energy, alertness, and focus in healthy people Evidence Grade C card
[Chamgap] Modafinil x improved mental energy, alertness, and focus in healthy people — Evidence Grade C·43. 5 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/modafinil-healthy-mental-energy-alertness-focus/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.